Education and Training
Effects of Low Dose Naltrexone in Fibromyalgia
Low Dose Naltrexone (LDN) has been reported anecdotally to reduce the symptoms of Fibromyalgia, a Chronic Multisystem Illness. The drug may work by regulating natural pain-reducing systems. In this study, we will administer both LDN and placebo to a small group of individuals with Fibromyalgia and Gulf War Syndrome, both Chronic Multisymptom Illnesses, to assess the drug's efficacy in treating the condition.
Stanford is currently not accepting patients for this trial.
Intervention(s):
- drug: Placebo - sugar pill
- drug: Low Dose Naltrexone
Eligibility
Inclusion Criteria:
Currently suffering from moderate to severe Fibromyalgia or symptoms of Gulf War Syndrome
Age 18-65. Not taking any opioid analgesic Not pregnant or planning to become pregnant.
Exclusion Criteria:
Any known allergy to naltrexone or naloxone. Actual or planned pregnancy.
Ages Eligible for Study
18 Years - 65 Years
Genders Eligible for Study
All
Not currently accepting new patients for this trial
Contact Information
Stanford University
School of Medicine
300 Pasteur Drive
Stanford,
CA
94305
Jarred Younger
Not Recruiting